Articles & Issues
- Language
- English
- Conflict of Interest
- In relation to this article, we declare that there is no conflict of interest.
- Publication history
-
Received August 25, 2017
Accepted February 2, 2018
-
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0) which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © KIChE. All rights reserved.
All issues
Growth retardation of diflunisal in antisolvent crystallization
Department of Chemical Engineering, Kyungpook National University, Daegu 41566, Korea
Korean Journal of Chemical Engineering, September 2018, 35(9), 1860-1866(7), 10.1007/s11814-018-0014-z
Download PDF
Abstract
Diflunisal, an analgesic anti-inflammatory drug, was recrystallized from acetone solution using water and carbon dioxide as antisolvents. The crystallized diflunisal showed an acicular crystal habit with a very high aspect ratio. Growth retardation of diflunisal crystals was observed when ultrasound was added during the recrystallization and when habit-modifying agents were applied to the system. For example, an increase in sebacic acid concentration from 0.229 to 2.132 wt% lowered the aspect ratio of the crystal from 62 to 8.5, while an increase in Span 83 concentration from 1.712 to 4.415 wt% reduced the aspect ratio from 11 to 4.0. Differential scanning calorimetry and X-ray diffraction analysis revealed that the presence of ultrasound and habit-modifying agents may induce structural modifications as well as the growth retardation of diflunisal crystals.
References
Prosapio V, Reverchon E, De Marco I, J. Supercrit. Fluids, 107, 106 (2016)
Cuadra IA, Cananas A, Cheda JAR, Martinez-Casado FJ, Pando C, J. CO2 Utiliz., 13, 29 (2016)
Neurohr C, Marchivie M, Lecomte S, Cartigny Y, Couvrat N, Sanselme M, Subra-Paternault P, Cryst. Growth Des., 15, 4616 (2015)
Kaialy W, Larhrib H, Chikwanha B, Shojaee S, Nokhodchi A, Int. J. Pharm., 464, 53 (2014)
Park SJ, Yeo SD, J. Supercrit. Fluids, 47(1), 85 (2008)
Myerson AS, Handbook of Industrial Crystallization, 2nd Ed., Chapter 3, Butterworth Heinemann, Boston (2002).
Van Rosmalen GM, J. Cryst. Growth, 99, 1053 (1990)
Thompson C, Davies MC, Roberts CJ, Tendler SJB, Wilkinson MJ, Int. J. Pharm., 280, 137 (2004)
Cotton ML, Hux RA, Analyt. Profil. Drug Subst., 14, 491 (1985)
Giammona G, Cavallaro G, Pitarresi G, Ventura C, Palazzo S, Int. J. Pharm., 105, 57 (1994)
Martinez-Oharriz MC, Martin C, Goni MM, Rodriguez-Espinosa C, De Ilarduya-Apaolaza MCT, Sanchez M, J. Pharm. Sci., 83, 174 (1994)
Ford JL, Timmins P, Pharmaceutical Thermal Analysis, Ellis-Horwook Ltd., Chichester, U.K. (1989).
Cuadra IA, Cananas A, Cheda JAR, Martinez-Casado FJ, Pando C, J. CO2 Utiliz., 13, 29 (2016)
Neurohr C, Marchivie M, Lecomte S, Cartigny Y, Couvrat N, Sanselme M, Subra-Paternault P, Cryst. Growth Des., 15, 4616 (2015)
Kaialy W, Larhrib H, Chikwanha B, Shojaee S, Nokhodchi A, Int. J. Pharm., 464, 53 (2014)
Park SJ, Yeo SD, J. Supercrit. Fluids, 47(1), 85 (2008)
Myerson AS, Handbook of Industrial Crystallization, 2nd Ed., Chapter 3, Butterworth Heinemann, Boston (2002).
Van Rosmalen GM, J. Cryst. Growth, 99, 1053 (1990)
Thompson C, Davies MC, Roberts CJ, Tendler SJB, Wilkinson MJ, Int. J. Pharm., 280, 137 (2004)
Cotton ML, Hux RA, Analyt. Profil. Drug Subst., 14, 491 (1985)
Giammona G, Cavallaro G, Pitarresi G, Ventura C, Palazzo S, Int. J. Pharm., 105, 57 (1994)
Martinez-Oharriz MC, Martin C, Goni MM, Rodriguez-Espinosa C, De Ilarduya-Apaolaza MCT, Sanchez M, J. Pharm. Sci., 83, 174 (1994)
Ford JL, Timmins P, Pharmaceutical Thermal Analysis, Ellis-Horwook Ltd., Chichester, U.K. (1989).
